Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 14, 2018 - Issue
Submit an article Journal homepage
72
Views
10
CrossRef citations to date
0
Altmetric
Review

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

Yu-Tuan Wu1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]
,
Zhou Xu1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]
,
Ke Zhang2 Department of Orthopedics, Children’s Hospital of Chongqing Medical University, Chongqing 400020, China
,
Jiu-song Wu3 Department of General Surgery, Children’s Hospital of Chongqing Medical University, Chongqing 400020, China
,
Xin Li1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]
,
Bilal Arshad1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]
,
Ying-Cun Li3 Department of General Surgery, Children’s Hospital of Chongqing Medical University, Chongqing 400020, China
,
Zhong-Liang Wang2 Department of Orthopedics, Children’s Hospital of Chongqing Medical University, Chongqing 400020, China
,
Hong-Yuan Li1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]
,
Kai-Nan Wu1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]
&
Ling-Quan Kong1 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, [email protected]Correspondence[email protected]
 show all
Pages 1789-1797 | Published online: 26 Sep 2018

Figures & data

Figure 1 References selection flow diagram.

Figure 1 References selection flow diagram.

Figure 2 The pooled absolute rate of pCR for the concurrent (A) and nonconcurrent (B) use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Abbreviations: HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.
Figure 2 The pooled absolute rate of pCR for the concurrent (A) and nonconcurrent (B) use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Figure 3 The pooled OR of the pCR for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Abbreviations: HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.
Figure 3 The pooled OR of the pCR for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Figure 4 The pooled OR of secondary outcomes for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Abbreviations: HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.
Figure 4 The pooled OR of secondary outcomes for the comparison of the concurrent vs nonconcurrent use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.